Pipeline

The Best Target & The Best Chemical

Overview

Pharos iBio aims for global technology out-licensing by developing new drugs focusing on treatments for rare and refractory diseases through Chemiverse, an AI-based new drug development platform.

  • PHI-101-OC
    (Ovarian Cancer)

    Global Market Size KRW 5.3T
  • PHI-101-TNBC
    (Triple Negative
    Breast Cancer)

    Global Market Size KRW 2.2T
  • PHI-101-AML
    (Acute Myelogenous
    Leukemia)

    Global Market Size KRW 570.4B
  • PHI-101-RS
    (Radiation
    Sensitizer)

    Global Market Size KRW 1.2T
  • PHI-201
    (K-RAS protein
    inhibitor)

    Global Market Size KRW 400B
  • PHI-401
    (ALK resistance
    protein inhibitor)

    Global Market Size KRW 2.9T
  • PHI-301
    (FAK Hub protein
    inhibitor)

    Global Market Size KRW 1.5T
  • PHI-501
    (pan-RAF/DDRs
    inhibitor)

    Global Market Size KRW 4.5T
Pipeline Development Progress
구분 Pipeline Lead & Tox Pre-Clinical IND Phase 1 Phase 2
PHI-101 AML
(Acute Myelogenous Leukemia)
OC
(Ovarian Cancer)
TNBC
(Triple Negative Breast Cancer)
Radiation Sensitizer
PHI-201 K-Ras Hub-protein inhibitor
PHI-301 FAK Hub-protein inhibitor
PHI-401 ALK 저항성 Protein inhibitor
PHI-501 pan-RAF/DDRs inhibitor